Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Genflow Biosciences Plc ( (GB:GENF) ) has provided an announcement.
Genflow Biosciences Plc has announced its Annual General Meeting (AGM) will be held on June 12, 2025, in London. The company has made its AGM notice and annual report available on its website. This meeting is a significant event for stakeholders as it will provide insights into Genflow’s progress and future plans, particularly in the field of longevity research and the upcoming clinical trials for their lead compound GF-1002.
More about Genflow Biosciences Plc
Genflow Biosciences Plc, founded in 2020, is a UK-based biotechnology company with R&D facilities in Belgium. It is focused on pioneering gene therapies to slow the aging process, aiming to promote longer and healthier lives. The company’s lead compound, GF-1002, targets the SIRT6 gene and is set to begin clinical trials in 2025 to explore its potential in treating Metabolic Dysfunction-Associated Steatohepatitis (MASH), a prevalent chronic liver disease.
Average Trading Volume: 2,567,786
Technical Sentiment Signal: Sell
For detailed information about GENF stock, go to TipRanks’ Stock Analysis page.